The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
T Barbui - Seminars in hematology, 2004 - Elsevier
Polycythemia vera (PV) and essential thrombocythemia (ET) may rarely evolve into acute
leukemia as part of their natural history. Cytogenetic abnormalities and the use of alkylating
agents can enhance the risk of this transformation. Hydroxyurea (HU) has a limited, if any,
leukemogenic potential and should be considered the current cytotoxic drug for patients at
high risk for thrombotic complications, ie, those with age above 60 years or previous
thrombotic events. Interferon-α (IFN-α) and anagrelide are known not to be leukemogenic …
leukemia as part of their natural history. Cytogenetic abnormalities and the use of alkylating
agents can enhance the risk of this transformation. Hydroxyurea (HU) has a limited, if any,
leukemogenic potential and should be considered the current cytotoxic drug for patients at
high risk for thrombotic complications, ie, those with age above 60 years or previous
thrombotic events. Interferon-α (IFN-α) and anagrelide are known not to be leukemogenic …